News and announcements

Dr. Goodenowe guest on Living Beyond 120 podcast

Thank you to Mark Young and Dr. Jeffrey R. Gladden, MD, FACC for hosting Dr. Goodenowe, Founder and CEO of Prodrome Sciences, on the Living Beyond 120 podcast. The podcast is focused on health and human longevity by examining “the latest scientific research, technology and bio-hacks to uncover the truth

Read More

Join us at the Peptide World Congress, Las Vegas, Sep 10-11

Prodrome Sciences will be attending SSRP’s Peptide World Congress held September 10th – 11th at the Four Seasons – Mandalay Bay, Las Vegas. Dr. Dayan Goodenowe will be hosted by Dr. Seeds for a fireside chat on Saturday, September 11. The Pioneers and Leaders of Anti-Aging and Regenerative Medicine will

Read More

Prodrome blood tests available in Europe

We are pleased to announce that our blood tests are available in Europe through CoLabs. Based in the UK, Colabs is a laboratory agency servicing the whole of Europe. Colabs supports practitioners with access to advanced, specialist laboratory testing from around the world.  Visit www.colabeu.com for a list of practitioners

Read More

Dr. Goodenowe guest on Jillian Michael’s podcast

Dr. Dayan Goodenowe was recently a guest on Jillian Michael’s podcast. The conversation covered topics from genetics, to environmental toxins, to fasting, to resistance training, and even grass fed beef. It is a conversation you don’t want to miss if you want to hear from Dr. Goodenowe’s diverse, practical knowledge.

Read More

Dr. Goodenowe guest on 15-Minute Matrix podcast

Dr. Dayan Goodenowe was recently a guest on Andrea Nakayama’s podcast, the 15-Minute Matrix. From her website, she describes the podcast as “Plasmalogens: What are they and how do they work in the body? It goes deep. Really deep! Join me and Dr. Dayan Goodenowe as we discuss plasmalogens and

Read More

Breaking Alzheimer’s book now available!

Dr. Dayan Goodenowe’s book, Breaking Alzheimer’s, is now available to purchase! Breaking Alzheimer’s is Dr. Goodenowe’s story of personal and scientific perseverance. The biochemical mechanisms of neurological disease is his area of expertise and was his area of expertise for 15 years before he serendipitously discovered that low plasmalogen levels were

Read More

Dr. Goodenowe guest on Redefining Medicine podcast

Thank you to the American Academy of Anti-Aging Medicine (A4M) for hosting Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences on their latest podcast. From their website, their “podcast Redefining Medicine captures the journeys and stories of healthcare practitioners and innovative visionaries, all of whom are actively changing the way

Read More

Dr. Goodenowe to present at Brain Health Summit

Dr. Goodenowe has been invited to present alongside other leaders in anti-aging medicine at the A4M Brain Health Summit June 26-27. He shares his expertise in two sessions: Good Oxygen and Bad Oxygen – Mitochondria, Oxidative Stress and Neurodegeneration and Good Fat and Bad Fat – Plasmalogens, Membranes, and Brain

Read More

Blood tests now available in Australia

We are pleased to announce that our blood tests are now available in Australia and soon New Zealand, where you can now get our ProdromeScan blood test or PlasmalogenPLUS blood tests! Available in Australia through our exclusive distributor OptiLabs by Evergreen Doctors. To learn more about the test availability in

Read More

Dr. Goodenowe’s Physician Roundtable Group

All healthcare professionals part of the ProdromeScan Certification Course are invited to Dr. Goodenowe’s Physician Roundtable Group. This group meets regularly through video conference to discuss case studies from the doctors using the ProdromeScan blood test with their patients, with a particular focus on diseases of interest. The conference videos are uploaded to the Group and available to all Group Members. 

Read More

Book pre-order now available

The anticipated release date for Dr. Dayan Goodenowe’s new book is June 25, 2021. Pre-orders are now available for Breaking Alzheimer’s: A 15 Year Crusade to Expose the Cause and Deliver the Cure. Pre-order here. Breaking Alzheimer’s is Dr. Dayan Goodenowe’s story of personal and scientific perseverance. The biochemical mechanisms of

Read More

Educational Video Seminars

Dr. Goodenowe has over 30 years of diverse scientific research experience and has explored topics ranging from software, to mechanics, to theoretical physics, to neuroscience. From this vast knowledge, he creates regular presentations and videos exploring many topics of great interest to him and shares what he has learned. Each

Read More

ProdromeScan Certification Course Launch

Dr. Dayan Goodenowe is passionate about sharing his knowledge of the biochemistry of health and disease. He has launched his ProdromeScan Certification Course to share this knowledge with you!   The ProdromeScan test is a multi-system blood test specifically designed to assist advanced functional medicine doctors in achieving optimal biochemical

Read More

Ben Greenfield Before and After Blood Test

Ben Greenfield is a leader in health and fitness coaching and has been named the one of the world’s top 100 most influential people in health and fitness. He completed his follow up ProdromeScan blood test after taking our ProdromeNeuro plasmalogen supplement for three months. Dr. Dayan Goodenowe, Founder and CEO of

Read More

New PlasmalogenPLUS Blood Test Launch

  We are pleased to announce the launch of our new blood test, PlasmalogenPLUS. The new test is a simplified report that measures plasmalogen molecules in addition to other key ethanolamine phospholipids. This blood test makes plasmalogen testing more accessible at half the price of our full ProdromeScan Blood Test! We offer

Read More

Dr. Goodenowe guest on podcast

Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, joined host Daniel Eisenman on his podcast Breaking Normal to discuss plasmalogens, the ProdromeScan blood test, and the science and research behind the Prodrome products. It was a pleasure to speak to Daniel and we thank him for the invitation and his time!

Read More

Upcoming webinar

Plasmalogen Deficiency and its Role in Neurodegenerative Diseases and Accelerated Mortality: What Every Doctor Must Know Please join host Dr. Mitchell Fleisher and presenter Prodrome Sciences Founder and CEO Dr. Dayan Goodenowe, for a live webinar on Saturday, February 20th at 10:00 am PST. Learn: What plasmalogens are and why

Read More

ProdromeScan and fitness

Dr. Dayan Goodenowe had the pleasure of introducing the power of the ProdromeScan blood test to Ben Greenfield. You can read his article about his experience and watch a video of Dr. Goodenowe reviewing his results here. Ben is a leader in health and fitness coaching and has been named the one

Read More

Dr. Gundry Podcast Interview

  Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, was invited to discuss plasmalogens on the Dr. Gundry Podcast. It was a pleasure to speak with Dr. Gundry to explain the extensive research and clinical trial evidence behind plasmalogens and dementia as well as the importance of supplementing with

Read More

New product launch

  ProdromeGlia plasmalogen supplement available in capsules. ProdromeGlia is a biochemical plasmalogen supplement designed to restore, maintain, and optimize glia membranes and to create a biochemical reserve of critical membrane building material for glia membrane repair when needed. Our ProdromeGlia plasmalogen supplement is now available in capsule form! Glia are

Read More

Dr. Goodenowe presents cancer research

  Dr. Goodenowe presents colon cancer, pancreatic cancer and plasmalogen supplementation research. Dr. Goodenowe presented recent clinical research results at a symposium at the 67th Annual Meeting of Japanese Society of Laboratory Medicine on November 22. He presented results from a study on 1,128 persons including 374 colorectal cancer subjects

Read More

Independent plasmalogen research published

  Multi-Study paper published in Nature Communications identifies plasmalogen deficiency as key biochemical deficit in Alzheimer’s. Another important paper was published by independent researchers confirming Dr. Goodenowe’s (Founder and CEO, Prodrome Sciences) original discovery and hypothesis that plasmalogen deficiency is the key underlying causative factor in Alzheimer’s. In this new paper, researchers

Read More

Breast cancer research

  ProdromeScan blood test identifies biomarker and biosystem dysfunctions in breast cancer. Prodrome Sciences and Kyoto Prefectural University presented the results from their collaboration on breast cancer biochemistry at the 28th Annual Meeting of The Japanese Breast Cancer Society. The collaboration investigated the biochemical status of women diagnosed with breast cancer

Read More

Dr. Goodenowe presenting at RAAD Festival

Dr. Dayan Goodenowe, Prodrome’s Founder and CEO, is presenting at this year’s RAAD Festival alongside leaders in longevity science. His presentation is on the Biochemical Basis of Longevity: How to measure and optimize human biochemistry for maximum lifespan. We look forward to the event this weekend! View the event information here. Contact

Read More

New prices with new technology!

We are proud to announce that due to strong sales and investment support, Prodrome Sciences has been able to upgrade manufacturing facilities for ourplasmalogen supplements. Prodrome is committed to passing cost-savings to our customers. Our goal is to ensure that every person has access to affordable and effective plasmalogen supplementation – and we just completed another major step on this path.  Last year, with

Read More

Plasmalogen supplementation review article published

Several recently published peer-reviewed research articles from independent and prestigious research institutions involving large, well-characterized populations of persons suffering from Alzheimer’s disease and related dementias have unanimously concluded that low blood plasmalogen levels are linked to dementia: as originally discovered and described by Dr. Dayan Goodenowe, Prodrome Sciences’ Founder and

Read More

Plasmalogen clinical trial underway

We are pleased to announce a clinical trial is underway using our ProdromeNeuro plasmalogen oil supplement in subjects with a confirmed diagnosis of mild to moderate dementia. The trial is taking place at the Neurological Associates of West Los Angeles clinic in Santa Monica, California, run by Dr. Sheldon Jordan,

Read More

New product launch

  ProdromeGTA supplement is now available. We are pleased to announce the launch of our new supplement, ProdromeGTA. The history and science behind ProdromeGTA is very interesting. In 1999, Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, invented a revolutionary technology called Non-Targeted Complex Sample Analysis. Dr. Goodenowe’s invention

Read More

Independent research on plasmalogens

  New publication from independent research validates Dr. Goodenowe’s original hypothesis on plasmalogens and Alzheimer’s. New research published from a study of 1,112 individuals in Australia further confirms that plasmalogen molecules are low in persons with Alzheimer’s disease. The authors found that low plasmalogens are associated with all risk factors of

Read More

Alzheimer’s and plasmalogen paper published

  Dr. Goodenowe and colleagues publish another paper linking low plasmalogens to Alzheimer’s disease. Dr. Goodenowe’s landmark research paper titled “Peripheral Ethanolamine Plasmalogen Deficiency – A Logical Causative Factor in Alzheimer’s Disease and Dementia” was originally published in 2007. Since then Dr. Goodenowe has continued to collaborate with leading researchers

Read More

Dr. Goodenowe guest on podcast

  Dr. Adam Rinde hosts Dr. Goodenowe to discuss the science and research behind plasmalogens. Thank you Dr. Adam Rinde for having Dr. Dayan Goodenowe, Founder and CEO, on your podcast to discuss the strong science behind our plasmalogen products. Click here to listen and click here to read more. 

Read More

Podcast interview

  Dr. Goodenowe on The Health Fix podcast. It was a pleasure to speak to Dr. Jannine Krause on the Health Fix Podcast about our plasmalogen oil supplement, our ProdromeScan blood test, and our research. Click here to listen to the podcast.

Read More

New plasmalogen product launch

ProdromeGlia plasmalogen oil is now available to provide omega-9 (oleic acid) plasmalogens. We are pleased to offer another important plasmalogen oil product through our valued healthcare professionals to help their patients achieve optimal health! ProdromeGlia is a biochemical plasmalogen supplement designed to restore, maintain, and optimize glia membranes and to

Read More

Dr. Goodenowe guest on podcast

Dr. Goodenowe talks about the genetics and metabolomics of Alzheimer’s the on ApoE4.info, Inc. podcast. ApoE4.info, Inc. is a non-profit group dedicated to understanding the APOE-ε4 allele and how it affects health. With personal genetic testing becoming so common now, many people are learning that they are at increased risk

Read More

New research on asthma, lung health, and plasmalogens

Research on asthma, lung function, and plasmalogens demonstrates how important plasmalogens are for many areas of health. Plasmalogen molecules are critical for optimal health. Levels decrease with age as the body can no longer make as much as it needs and the body uses up plasmalogens as anti-inflammatory and antioxidant

Read More

Prodrome in the News

  Dr. Goodenowe shares Prodrome Sciences’ vision for health and longevity. We are applying our technology to move beyond the treatment and prevention of diseases. Why be satisfied with the mere prevention of a negative outcome, like disease, when our technology and products can help people attain a positive outcome

Read More

Feature blog post

  We are pleased to share the exciting research behind plasmalogen molecules in a featured blog post on Dr. Kara Fitzgerald’s website. Read the article here to learn more about the role of plasmalogens in health and why you do not want to risk having low levels of these critical molecules. Contact

Read More

Dr. Goodenowe presents at longevity event

Thank you to People Unlimited for inviting Dr. Dayan Goodenowe to speak at the January Super Longevity Weekend in Scottsdale, Arizona. It was a pleasure to share Prodrome’s vision of optimizing biochemical health in order to achieve lasting health, vitality, and longevity.

Read More

Prodrome-Neuro validated in humans!

Successful first human trial of Prodrome-Neuro Plasmalogen Oil: a scientifically designed, natural, pure, synthetic plasmalogen precursor Prodrome-Neuro Plasmalogen Oil is a synthetically pure, natural, plasmalogen precursor designed to elevate specific plasmalogens in the blood. Low levels of plasmalogens are associated with an increased risk of Alzheimer’s disease and early death.

Read More

Collaborators present plasmalogen data

Collaborators at the Buck Institute and OpenOme presented exciting data on our Prodrome-Neuro Plasmalogen Oil in flies Promising early results of Prodrome-Neuro Plasmalogen Oil in flies was presented at the Bay Area Aging Meeting (BAAM) at Stanford University, California on December 5. The experiments were conducted by researchers from OpenOme

Read More

Prodrome-Neuro Plasmalogen Oil pre-orders open

Collaborators at the Buck Institute and OpenOme presented exciting data on our Prodrome-Neuro Plasmalogen Oil in flies We are excited to announce we are now taking pre-orders of our Prodrome-Neuro Plasmalogen Oil supplement for personal use. The product is currently available for research use only. We are working on completing

Read More

Important plasmalogen research published

Congratulations to researchers at Laval University for publishing important findings on plasmalogens in Parkinson’s disease model Recent research from Laval University demonstrates the critical role of plasmalogens in Parkinson’s disease. The research revealed that treatment of plasmalogens in a mouse model of Parkinson’s disease had anti-inflammatory effects in the gut and

Read More

Dr. Goodenowe presents pancreatic cancer test

Dr. Goodenowe presents to over 500 gastroenterologists at seminar in Japan We would like to thank the organizers of the 35th Annual Educational Seminar of the Japan Gastroenterology Study for the invitation for Dr. Goodenowe, Prodrome Sciences’ Founder and CEO, to speak to the over 500 gastroenterologists that attended the

Read More

Plasmalogen oil now available!

Prodrome Sciences’ Prodrome-Neuro plasmalogen oils are now available for research use We are excited to announce that our plasmalogen oils are now available! Currently for research use only, with the personal use supplements anticipated for launch within a year. Two versions of the plasmalogens oils are available: Super-DHA and Omega-9.

Read More

Dr. Goodenowe presents at the Dementia Prevention Conference in Japan

Plasmalogen research and clinical trial presented at the Dementia Prevention Conference in Japan Dr. Goodenowe, Founder of Prodrome Sciences, presented his research on plasmalogens and neurodegeneration and the strong clinical data supporting plasmalogen supplementation as a strategy to prevent and treat dementia and to increase longevity. He presented Prodrome Sciences’

Read More

Alzheimer’s and plasmalogens: major paper published

Prodrome Sciences publishes research demonstrating the role of plasmalogens in the cause of Alzheimer’s Plasmalogen molecules, critical lipids required for brain and nerve function, have been researched extensively since Dr. Goodenowe (Founder and CEO, Prodrome Sciences) first published his hypothesis about the role of plasmalogens in dementia in 2007. The Alzheimer’s

Read More

Alzheimer’s research published

Prodrome Sciences publishes research on the relationship between plasmalogens and the APOE e4 genotype Our published research shows that a person’s levels of plasmalogens, a critical lipid molecule required for brain and nerve function, is a better indicator of risk of Alzheimer’s disease than the established genetic risk factor APOE e4. This

Read More

Alzheimer’s Association funds plasmalogen clinical trial

Based upon Dr. Goodenowe’s research linking high plasmalogen levels with a low risk of Alzheimer’s disease, the Alzheimer’s Association (Chicago, USA) is funding a clinical trial to investigate the effects of Prodrome Sciences’ novel plasmalogen precursor supplement in persons diagnosed with mild Alzheimer’s disease. Plasmalogens are a type of lipid (fat)

Read More

Alzheimer’s research published

Prodrome Sciences publishes research results from a community trial of 1,205 persons (average age = 84) that showed that elderly persons with high blood plasmalogens had a dramatically lower rate of dementia (6%) versus persons with low blood plasmalogens (31%). In addition, it was observed that high blood plasmalogens was

Read More

We’re moving!

We are pleased to announce the opening of our new 4,000 square foot laboratory facility in Temecula, California. The new facility will house our advanced, high-resolution mass spectrometry research and development laboratory, CLIA biomedical laboratory, and cGMP therapeutics manufacturing laboratory. Prodrome Sciences’ first therapeutic product, a plasmalogen bioprecursor, is ready

Read More

Colorectal and pancreatic cancer biomarker study

Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention are analyzing over 3,000 samples of Japanese persons with confirmed diagnoses of colorectal or pancreatic cancer and persons of average risk. The goal of the research collaboration

Read More

3-year colorectal cancer program

Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention have completed year two of a three-year collaboration comparing the clinical mass spectrometric analysis of serum GTAs (gastrointestinal tract acids) and FIT (fecal immunohistochemical) tests for identifying

Read More

Plasmalogens and bipolar disorder

  Prodrome Sciences publishes paper with collaborators showing plasmalogen levels are lower in patients with bipolar disorder Plasmalogens are critical molecules needed for optimal health and nerve and brain function. The role of plasmalogens in neurodegenerative diseases such as Alzheimer’s is well established. This newest paper published with our collaborators

Read More

Dr. Kevin Perrott joins Prodrome Sciences

Prodrome Sciences is proud to announce a new board member and advisor, Dr. Kevin Perrott, of OpenOme and the Buck Institute for Research on Aging. After becoming a cancer survivor, Kevin has dedicated his life to the field of longevity. Prodrome Sciences and Kevin will work together to build a

Read More

Biomarker discovery research on aging, dietary lifestyles, and disease

Prodrome Sciences and Kyoto Prefectural University of Medicine (Department of Epidemiology for Community Health and Medicine) are proud to announce they have begun a collaborative biomarker research study to investigate longitudinal biomarker changes associated with dietary lifestyle diseases, dementia, cancer, and locomotive syndrome using Prodrome Sciences’ patented comprehensive metabolomics technology

Read More

Interview with Dr. Dayan Goodenowe

Prodrome Sciences and Kyoto Prefectural University of Medicine (Department of Epidemiology for Community Health and Medicine) are proud to announce they have begun a collaborative biomarker research study to investigate longitudinal biomarker changes associated with dietary lifestyle diseases, dementia, cancer, and locomotive syndrome using Prodrome Sciences’ patented comprehensive metabolomics technology

Read More

Independent validation of Dr. Goodenowe’s plasmalogen research

Independent validation of Dr. Dayan Goodenowe’s original research findings linking decreased blood plasmalogens with increased risk of dementia presented at the 2018 Alzheimer’s Association International Conference (AAIC). On July 24, the Alzheimer’s Association International Conference (AAIC) held a session titled “Gut-Liver-Brain Axis in Alzheimer’s Disease” where researchers from the multi-institutional Alzheimer’s Disease

Read More

Dr. Dayan Goodenowe to present colorectal cancer associated GTAs study results

Prodrome Sciences Inc.’s Founder and CEO, Dr. Dayan Goodenowe, will present the results of Prodrome Sciences’ Japanese population distribution study of colorectal cancer associated gastrointestinal tract acids (GTAs) at the 59th Annual Scientific Meeting of Japan Society of Ningen Dock International on August 30, 2018, in Niigata, Japan. Using Dr.

Read More

Prodrome Sciences’ blood tests launch in Eastern Europe

Prodrome Sciences Inc. is pleased to announce a distribution agreement with Neo Sanguis Srl for the sale of Prodrome Sciences’ multi-analyte risk assessment tests in Romania. Prodrome-CRC, a blood test to determine colorectal cancer risk, is the first product to launch in the region. Neo Sanguis Srl is based in

Read More

Prodrome Sciences’ blood tests launch in Japan

Prodrome Sciences Inc. and NK Medico are proud to announce they have agreed to an exclusive distribution agreement for the sale of Prodrome Sciences’ multi-analyte risk assessment tests in Japan. Prodrome Sciences has developed improved blood testing technology for identifying persons with a high risk of colorectal cancer or pancreatic

Read More

Psychiatric and neurological diseases biomarker research

Prodrome Sciences Inc. and the National Center of Neurology and Psychiatry (NCNP) in Japan are proud to announce they have initiated an integrated multi-disease research study to discover and validate blood and cerebral spinal fluid biomarkers for psychiatric and neurological diseases using Prodrome Sciences’ patented comprehensive metabolomics technology and biospecimens

Read More

Prodrome-CRC launch – blood test to assess colorectal cancer risk

Prodrome Sciences is proud to announce the commercial launch of Prodrome-CRC – the high-resolution/accurate mass blood test for assessing colorectal cancer risk. Prodrome-CRC is a simple blood test that requires no advance preparations and no fecal handling. The multi-analyte test accurately determines if a person has a Gastrointestinal Tract Acid

Read More

Prodrome-PAC launch – blood test to assess pancreatic cancer risk

Prodrome Sciences is proud to announce the commercial launch of Prodrome-PAC – the high-resolution/accurate mass blood test for assessing pancreatic cancer risk. Prodrome-PAC is a simple blood test that requires no advance preparation. The multi-analyte test accurately determines if a person has a pancreatic cancer specific biomarker deficiency. By knowing

Read More

Discovery and Translation Symposium

Prodrome Sciences is pleased to announce that Dr. Goodenowe has been invited to give a scientific presentation on October 26, 2017, at the Campus Alberta Neuroscience Symposium, Neurotechnology for Discovery and Translation. The title of Dr. Goodenowe’s talk is, “Bipolar Disorder: Biology, serum biomarkers, and opportunities to improve patient management”.

Read More

Public lecture on Alzheimer’s disease

Prodrome Sciences is pleased to announce that Dr. Goodenowe has been invited by the Prince Edward Island BioAlliance to deliver a public lecture on the current status of Alzheimer’s disease research at Holland College in Charlottetown, PEI, Canada on July 9, 2017. The title of Dr. Goodenowe’s lecture is, “The

Read More